Immune mechanisms and immunomodulatory therapies in steroid-resistant nephrotic syndrome
Authors:
Open Access
- 11 December 2025
- journal article
- review article
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2556486
Abstract
Steroid-resistant nephrotic syndrome (SRNS) is a complex and refractory kidney disease generally causing chronic kidney dysfunction, characterized by persistent proteinuria despite prolonged corticosteroid therapy. This review comprehensively explores the mechanisms of immunity driving SRNS, mainly focusing on the complex function network within immune cells, pro-inflammatory cytokines, and podocyte injury. Current immunosuppressive therapies show limited efficacy, prompting exploration of precision immunomodulatory strategies. Emerging approaches include IL-17 or low-dose IL-12 modulation, proteasome or CD38 blockade, C5/factor B inhibition, and Rho kinase or caspase inhibition. Additionally, personalized strategies leveraging genetic profiling and biomarker-guided therapies are advancing tailored interventions. These targeted therapies address SRNS heterogeneity while minimizing systemic immunosuppression, offering new promise for halting disease progression. Future directions emphasize combinatorial regimens and mechanistic stratification to optimize therapeutic outcomes.Keywords
This publication has 81 references indexed in Scilit:
- Complement activation in diseases presenting with thrombotic microangiopathyEuropean Journal of Internal Medicine, 2013
- Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGOPediatric Nephrology, 2012
- Rho-kinase inhibition prevents proteinuria in immune-complex-mediated antipodocyte nephritisAmerican Journal of Physiology-Renal Physiology, 2012
- Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced VasculitisNew England Journal of Medicine, 2011
- Rituximab Targets Podocytes in Recurrent Focal Segmental GlomerulosclerosisScience Translational Medicine, 2011
- Th17/Treg imbalance in adult patients with minimal change nephrotic syndromeClinical Immunology, 2011
- COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafnessJournal of Clinical Investigation, 2011
- Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndromeNephrology Dialysis Transplantation, 2010
- Efficacy and Safety of Tacrolimus Versus Cyclosporine in Children With Steroid-Resistant Nephrotic Syndrome: A Randomized Controlled TrialAmerican Journal of Kidney Diseases, 2009
- Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndromePediatric Nephrology, 2008